ACRIVON THERAPEUTICS INC (ACRV) Stock Price, Forecast & Analysis
NASDAQ:ACRV • US0048901096
ACRV Key Statistics, Chart & Performance
The current stock price of ACRV is 1.5 USD. In the past month the price decreased by -22.68%. In the past year, price decreased by -71.75%.
ACRV Technical Analysis
ACRV Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACRV. ACRV has a great financial health rating, but its profitability evaluates not so good.
ACRV Financial Highlights
Over the last trailing twelve months ACRV reported a non-GAAP Earnings per Share(EPS) of -2.13. The EPS increased by 21.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.26% | ||
| ROE | -63.57% | ||
| Debt/Equity | 0 |
ACRV Forecast & Estimates
15 analysts have analysed ACRV and the average price target is 11.73 USD. This implies a price increase of 682% is expected in the next year compared to the current price of 1.5.
ACRV Ownership
ACRV Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.73 | 405.578B | ||
| AMGN | AMGEN INC | 16.99 | 204.31B | ||
| GILD | GILEAD SCIENCES INC | 16.55 | 185.891B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.91 | 122.042B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.62 | 83.206B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.69 | 43.51B | ||
| INSM | INSMED INC | N/A | 33.916B | ||
| NTRA | NATERA INC | N/A | 29.129B | ||
| BIIB | BIOGEN INC | 12.83 | 28.815B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.433B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ACRV
Company Profile
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. The company is headquartered in Watertown, Massachusetts and currently employs 75 full-time employees. The company went IPO on 2022-11-15. The company uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. The company is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
Company Info
ACRIVON THERAPEUTICS INC
480 Arsenal Way, Suite 100
Watertown MASSACHUSETTS US
Employees: 75
Phone: 16172078979
ACRIVON THERAPEUTICS INC / ACRV FAQ
Can you describe the business of ACRIVON THERAPEUTICS INC?
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. The company is headquartered in Watertown, Massachusetts and currently employs 75 full-time employees. The company went IPO on 2022-11-15. The company uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. The company is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
What is the stock price of ACRIVON THERAPEUTICS INC today?
The current stock price of ACRV is 1.5 USD.
What is the dividend status of ACRIVON THERAPEUTICS INC?
ACRV does not pay a dividend.
What is the ChartMill technical and fundamental rating of ACRV stock?
ACRV has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does ACRIVON THERAPEUTICS INC belong to?
ACRIVON THERAPEUTICS INC (ACRV) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for ACRIVON THERAPEUTICS INC?
ACRIVON THERAPEUTICS INC (ACRV) has a market capitalization of 47.34M USD. This makes ACRV a Nano Cap stock.
Can you provide the short interest for ACRV stock?
The outstanding short interest for ACRIVON THERAPEUTICS INC (ACRV) is 8.08% of its float.